NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

VACH

Voyager Acquisition Corp

Jul 03 • 01:30PM ET

10.41

Dollar change +0.01
Percentage change 0.10	%

Financial • Shell Companies • USA • NASD

Scroll to Statements

Index	-	P/E	49.69	EPS (ttm)	0.21	Insider Own	20.00%	Shs Outstand	25.30M	Perf Week	0.19%
Market Cap	329.16M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	25.30M	Perf Month	0.97%
Enterprise Value	328.71M	PEG	-	EPS next Q	-	Inst Own	70.76%	Short Float	0.01%	Perf Quarter	2.76%
Income	6.63M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.03	Perf Half Y	3.94%
Sales	0.00M	P/B	1.32	EPS next Y	-	ROA	5.05%	Short Interest	0.00M	Perf YTD	3.89%
Book/sh	7.91	P/C	731.48	EPS next 5Y	-	ROE	5.30%	52W High	11.20 -7.05%	Perf Year	-
Cash/sh	0.01	P/FCF	-	EPS past 3/5Y	- -	ROIC	2.65%	52W Low	9.95 4.62%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	0.03% 0.08%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.01	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.81	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	70.36	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	5.81	EPS Q/Q	4906.25%	SMA20	0.29%	Beta	-	Target Price	-
Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	0.92%	Rel Volume	0.05	Prev Close	10.40
Employees	3	LT Debt/Eq	0.00	Earnings	-	SMA200	2.67%	Avg Volume	127.47K	Price	10.41
IPO	Sep 30, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	6,700	Change	0.10%

May-29-25 06:34PM	VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform (GlobeNewswire)
May-20-25 12:10PM	VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer (GlobeNewswire)
May-05-25 12:59PM	VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program (GlobeNewswire)
Apr-23-25 01:09AM	VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies (GlobeNewswire)

Voyager Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on December 19, 2023 and is headquartered in Houston, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VACH

Voyager Acquisition Corp

Upgrade your FINVIZ experience